ARC-520: Phase IIb started

Arrowhead began the open-label, Australian and New Zealand Phase IIb MONARCH (Heparc-2008) trial to evaluate 2 mg/kg IV ARC-520 every 4 weeks for 48 weeks alone or with entecavir and Pegasys peginte...